Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 14;36(23):e166.
doi: 10.3346/jkms.2021.36.e166.

Developing a Framework for Pandemic COVID-19 Vaccine Allocation: a Modified Delphi Consensus Study in Korea

Affiliations

Developing a Framework for Pandemic COVID-19 Vaccine Allocation: a Modified Delphi Consensus Study in Korea

Min Joo Choi et al. J Korean Med Sci. .

Abstract

Background: This study presents a framework for determining the allocation and distribution of the limited amount of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Methods: After analyzing the pandemic strategies of the major organizations and countries and with a literature review conducted by a core panel, a modified Delphi survey was administered to 13 experts in the fields of vaccination, infectious disease, and public health in the Republic of Korea. The following topics were discussed: 1) identifying the objectives of the vaccination strategy, 2) identifying allocation criteria, and 3) establishing a step-by-step vaccination framework and prioritization strategy based on the allocation criteria. Two rounds of surveys were conducted for each topic, with a structured questionnaire provided via e-mail in the first round. After analyzing the responses, a meeting with the experts was held to obtain consensus on how to prioritize the population groups.

Results: The first objective of the vaccination strategy was maintenance of the integrity of the healthcare system and critical infrastructure, followed by reduction of morbidity and mortality and reduction of community transmission. In the initial phase, older adult residents in care homes, high-risk health and social care workers, and personal support workers who work in direct contact with coronavirus disease 2019 (COVID-19) patients would be prioritized. Expansion of vaccine supply would allow immunization of older adults not included in phase 1, followed by healthcare workers not previously included and individuals with comorbidities. Further widespread vaccine supply would ensure availability to the extended adult age groups (50-64 years old), critical workers outside the health sector, residents who cannot socially distance, and, eventually, the remaining populations.

Conclusion: This survey provides the much needed insight into the decision-making process for vaccine allocation at the national level. However, flexibility in adapting to strategies will be essential, as new information is constantly emerging.

Keywords: COVID-19; Distribution; Korea; Policy; Survey; Vaccines.

PubMed Disclaimer

Conflict of interest statement

The opinions expressed by authors contributing to this article do not necessarily reflect the opinions of the Korea Disease Control and Prevention Agency or the institutions with which the authors are affiliated. The authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1. Process of creating a framework for allocation and prioritization of coronavirus disease 2019 vaccination.
Fig. 2
Fig. 2. Process of building consensus (the modified Delphi consensus process).

Similar articles

Cited by

References

    1. World Health Organization. Weekly epidemiological update on COVID-19 - 6 April 2021. [Updated April 4, 2021]. [Accessed April 6, 2021]. https://www.who.int/publications/m/item/weekly-epidemiological-update-on....
    1. European Centre for Disease Prevention and Control. Rapid risk assessment: coronavirus disease 2019 (COVID-19) in the EU/EEA and the UK – eighth update. 8 April 2020. [Updated April 8, 2020]. [Accessed November 29, 2020]. https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-rapid-....
    1. Centers for Disease Control and Prevention. COVID data tracker. Nationwide commercial laboratory seroprevalence survey. [Accessed March 2, 2021]. https://covid.cdc.gov/covid-data-tracker/#national-lab.
    1. European Centre for Disease Prevention and Control. Immune responses and immunity to SARS-CoV-2. [Accessed November 29, 2020]. https://www.ecdc.europa.eu/en/covid-19/latest-evidence/immune-responses.
    1. Rostami A, Sepidarkish M, Leeflang MM, Riahi SM, Nourollahpour Shiadeh M, Esfandyari S, et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clin Microbiol Infect. 2021;27(3):331–340. - PMC - PubMed

MeSH terms

Substances